Atrial Fibrillation

This channel includes news and new technology innovations for the treatment of atrial fibrillation, also referred to as AF or afib. AF is a cardiac arrhythmia caused by irregular and often rapid heart rate. It is caused by the upper chambers (the atria) beating irregularly and uncoordinated with the lower  ventricle chambers of of the heart. Symptoms include weakness with heart palpitations and shortness of breath. The conditional can lead to an increased risk of stroke and heart failure. AF episodes can cause the blood in the atria to stagnate and form clots, usually within the left atrial appendage (LAA). The clots can flow to the brain and cause a stroke. Treatments include anticoagulation therapy to dissolve clots, catheter or surgical ablation and LAA occlusion

POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020

March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing...

OTC ECG devices

OTC ECG devices can help detect abnormal heart rhythms in the general population, and this technology will continue to improve.

Feature | ECG | March 11, 2020

Apple created a stir when it...

Several wearable, less-obtrusive ECG monitors fhave been cleared by the FDA for longer wear. This example is Cardiac Insight’s Cardea SOLO device. 

Several wearable, less-obtrusive ECG monitors have been cleared by the FDA for longer wear. This example is Cardiac Insight’s Cardea SOLO device. 

Feature | ECG | February 19, 2020

When the patients of...

The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess Abbott's Amplatzer Amulet left atrial appendage (LAA) occluder for people with atrial fibrillation (AF or AFib). 
News | Left Atrial Appendage (LAA) Occluders | February 03, 2020

February 3, 2020 — The U.S. Food and Drug Administration (FDA) has approved a the...

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System.

News | Atrial Fibrillation | January 31, 2020

January 31, 2020 – The U.S. Food and Drug Administration (FDA) has given Medtronic approval to proceed with an...

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019

December 27, 2019 — The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics...

Peter Weiss, M.D., explains a Stereotaxis robotically navigated cardiac ablation procedure at Banner University Medicine Heart Institute.

Peter Weiss, M.D., explains a Stereotaxis robotically navigated cardiac ablation procedure at Banner University Medicine Heart Institute.

Feature | EP Lab | December 23, 2019 | J. Peter Weiss, M.D., MSc

Robotic technology, which helps...

Michigan Hospital Improves Post-CABG Outcomes Using Proactive Amiodarone Protocol
News | Cardiovascular Surgery | October 23, 2019

October 23, 2019 — Proactive administration of amiodarone to patients recovering from a common heart surgery shows...

Frequent Drinking Greater Risk Factor for Heart Rhythm Disorder Than Binge Drinking

Image courtesy of the American Heart Association.

News | Atrial Fibrillation | October 22, 2019

October 22, 2019 —  Drinking small amounts of alcohol frequently is linked with a higher likelihood of...

Fitbit trackers could help detect atrial fibrillation
News | Wearables | October 17, 2019

October 17, 2019 — The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in...

Kardium Announces Successful Results From GLOBAL-AF Study
News | EP Mapping and Imaging Systems | October 15, 2019

October 15, 2019 — Kardium Inc. announced that the Globe...

The life of Afib patient Glynn Crawford was saved three days after being prescribed a Zoll LifeVest wearable defibrillator by his cardiologist Barbara Williams, M.D., at   University Hospitals Ahuja Medical CenterShe identified him as a high-risk for sudden cardiac arrest.

The life of Afib patient Glynn Crawford was saved three days after being prescribed a Zoll LifeVest wearable defibrillator by his cardiologist Barbara Williams, M.D., at   University Hospitals Ahuja Medical CenterShe identified him as a high-risk for sudden cardiac arrest.

Feature | Sudden Cardiac Arrest | October 07, 2019

October 7, 2019 — Glynn Crawford was hospitalized at University...

Overlay Init